Abstract
Indian Journal of Modern Research and Reviews, 2026; 4(2): 442-446
Interleukin-39 as an Emerging Biomarker Cytokine in patients with type 2 diabetes Mellitus Diagnosis: Narrative review
Author Name: Hasan. R. Hamood, Hanan. R. Hamoud, Rana Talib Fakher Al-Nafakh, Hassan Sh. Kahait
Abstract
<p>It is a worldwide complicated metabolic disorder linked to impaired insulin action, chronic low-grade inflammation, and dysfunctional β-cells. Interleukin-39 (IL-39) has been identified as a new cytokine associated with immune modulation and metabolic dysfunction recently. Recent research has highlighted IL-39 as a biomarker in and an interventional target for T2DM. That review provides a brief of the present evidence on IL‑39 biology and its relevance to T2DM pathophysiology.</p>
Keywords
Interleukin 39(IL-39), Diabetes mellitus (T2DM), participants, healthcare
